The Personal Connected Health Alliance (PCHAlliance) and the newly formed Digital Therapeutics Alliance (DTA) have formed a strategic partnership to further establish the field of digital therapeutics. This partnership will combine the infrastructure, reach and resources of PCHAlliance and the expertise, thought leadership, and focus of DTA.
Announced at the 9th annual Connected Health Conference in Boston, PCHAlliance has also launched a new Digital Therapeutics Task Force, which will draw on DTA's subject matter expertise to focus on an initial set of high priority projects for both organizations. The task force will be open to PCHAlliance member companies, as well as allied associations and non-corporate thought leaders by invitation only. Pierre Leurent, CEO of Voluntis, a PCHAlliance member organization, and one of the founding members of the Digital Therapeutics Alliance, will serve as the task force chair.
"Digital therapeutics companies are proving, via rigorous clinical studies — and even regulatory approval — that connected health technologies can provide measurable clinical benefit, at least as good as some medication," Patty Mechael, PhD, MHS, Executive Vice President of PCHAlliance, said in a statement. "We are pleased to partner with the Digital Therapeutics Alliance to combine our resources to advance the field, galvanize key stakeholders, focus on developing standards of quality and work towards improving health outcomes through this newly developing sub-domain of personal connected health."
The term "digital therapeutics" refers to digital technology or software to treat a medical condition, used alone and in combination with conventional drug therapies. Digital therapeutics include mobile apps, wearable sensors, health monitoring devices or software that can change an individual's behavior in order to achieve positive clinical outcomes and, thereby better control the cost of care. A recent analyst report predicted that the digital therapeutics market will reach about $9 billion by 2025.
"Digital therapeutics companies are developing clinically validated tools that are improving value and lowering costs. These companies are harnessing the power of digital tools to improve disease management," added Pierre Leurent. "The field is evolving, so there is a need for digital therapeutics companies to come together, to clearly delineate the market, define the benefits and secure regulatory, reimbursement, provider and policy support."